NY-ESO-1 Therapy Renewed Enthusiasm Underscored by New Checkpoint Inhibitors
NY-ESO-1 targeting immunotherapies are seeing renewed clinical development interest as the antigen is widely expressed in certain solid...
NY-ESO-1 Therapy Renewed Enthusiasm Underscored by New Checkpoint Inhibitors
Democratizing Antibodies
FDA Review Policies for PD-1/PD-L1 Inhibitors Spark Expert Debate
ISSUE 11
Dr. Leon Reyfman, CEO of Advanced Clinical Laboratory Solutions, Inc
Issue10
Dr. Kyung Sun, Chairman of Osong Medical Innovation Foundation
PCSK9 Inhibitor Competition: Amgen, Scanofi, and Regeneron Show Equally Decent CVOT Outlooks
South Korea Trials Drive Further Opportunities for Global Pharma and CROs
Issue10